investor relations Archives

ive professionals meet around a conference table with laptops and calendars, beside a whiteboard highlighting December EoE data and EPRX.

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. October 27, 2026 359Views 0Likes

With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 503Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Storm-battered “Physical AI” data center connected to a power grid, illustrating AI infrastructure, resilient energy systems and 24/7 computing reliability.

The “Physical AI” Economy: Compute, Energy and Resilience Move to Center Stage During This Weekend’s nor’easter & Beyond -( $AMZN $MSFT $NVDA $ORCL $PSKY $SOC $QCOM )

by John F. Heerdink, Jr. September 27, 2026 494Views 0Likes

Wall Street’s latest AI conversation is becoming less about clever chatbots and more about the decidedly unglamorous work of power, chips, networks, security and uptime. That shift may be constructive for investors: it broadens the AI opportunity from a small club of…

Illustrated editorial image showing Palantir CEO Alex Karp, NVIDIA CEO Jensen Huang and a business executive standing around a data-sovereignty server stack, with global network graphics, gold bars and the headline “Palantir’s Sovereign AI Bet Turns Data Control Into the Next Premium Asset.”

Palantir’s Sovereign AI Bet Turns Data Control Into the Next Premium Asset -( $NVDA $PLTR )

by John F. Heerdink, Jr. September 25, 2026 611Views 0Likes

Palantir Technologies Inc. (NASDAQ: PLTR) is advancing a distinctly bullish proposition for the AI economy: the winners will not merely own the largest models or the most GPUs; they will retain control of the proprietary operating knowledge that makes their businesses valuable in…

Alt text: Retro-style illustration showing a burger drive-thru and digital clinic connected to a central data cloud, illustrating how McDonald’s, ecommerce analytics and telehealth platforms are using data to create new digital revenue opportunities.

From Drive-Thru Screens to Digital Clinics, Data Is Becoming the New Storefront -( $AMWL $AMZN $MCD $SMWB $WMT

by John F. Heerdink, Jr. September 24, 2026 548Views 0Likes

McDonald’s Corp. (NYSE: MCD), Similarweb Ltd. (NYSE: SMWB), and Amwell (NYSE: AMWL) are pursuing distinctly different strategies, but their direction points to one increasingly investable conclusion: companies that own meaningful customer interactions are finding new ways to monetize the data, workflow and…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 236Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Tribe Public CEO Presentation and Q&A webinar graphic featuring Serina Therapeutics CEO Steven Ledger, NYSE: SER, promoting “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” with a global network map, molecular imagery, and Register Now call to action.

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

by John F. Heerdink, Jr. September 21, 2026 434Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…

Stylized world map showing the United States highlighted at the center, with glowing pink connection lines linking Los Angeles, Chicago, New York, Washington, D.C., London, Berlin, Beijing, Tokyo and Sydney—illustrating global investor engagement, corporate access and virtual CEO communication.

The New Premium Asset: Attention That Shows Up

by John F. Heerdink, Jr. September 21, 2026 299Views 0Likes

In an era when nearly every company can publish a deck, record a webcast and summon an algorithmic audience, the scarce asset is becoming more human: a room, or a virtual room, filled with people who actually care enough to listen, ask…

Knightscope’s Next Act: Why an Autonomous Security Force Could Turn a Fragmented Industry Into a Recurring-Revenue Opportunity -( $F $KSCP $LKQ $PLTR )

by John F. Heerdink, Jr. September 11, 2026 504Views 0Likes

Knightscope (NASDAQ: KSCP) is pursuing a bigger prize than selling robots: it is assembling an integrated, technology-enabled security service designed to combine autonomous machines, AI software, remote monitoring and licensed human agents under one accountable operating model. There is no shortage of…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 356Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Tag: investor relations

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

The “Physical AI” Economy: Compute, Energy and Resilience Move to Center Stage During This Weekend’s nor’easter & Beyond -( $AMZN $MSFT $NVDA $ORCL $PSKY $SOC $QCOM )

Palantir’s Sovereign AI Bet Turns Data Control Into the Next Premium Asset -( $NVDA $PLTR )

From Drive-Thru Screens to Digital Clinics, Data Is Becoming the New Storefront -( $AMWL $AMZN $MCD $SMWB $WMT

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care -( $SER $PFE $XBI )

The New Premium Asset: Attention That Shows Up

Knightscope’s Next Act: Why an Autonomous Security Force Could Turn a Fragmented Industry Into a Recurring-Revenue Opportunity -( $F $KSCP $LKQ $PLTR )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets